Alvotech Registered Aktie

3,62 EUR -0,20 EUR -5,24 %

21:31:47

STU

4,37 USD -0,27 USD -5,72 %

21:41:20

BTT

Alvotech Registered jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.1,17 Mrd. EUR

Div. Rendite0,00%

WKNA3DK8U

ISINLU2458332611

SymbolALVO

Alvotech Registered Aktien News

Sortieren:Datum Meistgelesen

03.04.24GlobeNewswireAlvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

22.03.24GlobeNewswireAlvotech Announces Increase in Number of Own Shares

20.03.24GlobeNewswireAlvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

05.03.24GlobeNewswireAlvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET

29.02.24GlobeNewswireAlvotech Appoints Interim Chief Quality Officer

26.02.24GlobeNewswireAlvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

24.02.24GlobeNewswireAlvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

15.02.24GlobeNewswireAlvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)

29.01.24GlobeNewswireAlvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

19.01.24GlobeNewswireAlvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04

10.01.24GlobeNewswireSTADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara

03.01.24GlobeNewswireAlvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)

29.11.23GlobeNewswireAlvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

28.11.23GlobeNewswireAlvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update

21.11.23GlobeNewswireAlvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET

14.11.23GlobeNewswireAlvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)

10.11.23GlobeNewswireSTADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara

07.11.23GlobeNewswireAlvotech to Present at the Jefferies 2023 London Healthcare Conference

12.10.23GlobeNewswireAlvotech Provides Update on Status of U.S. Biologics License Application for AVT04

05.10.23GlobeNewswireAlvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland

03.10.23GlobeNewswireAlvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)

25.09.23GlobeNewswireAlvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®

20.09.23GlobeNewswireAlvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)

11.09.23GlobeNewswireAlvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

05.09.23GlobeNewswireAlvotech Announces Changes to the Leadership Team

30.08.23GlobeNewswireAlvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update

29.08.23GlobeNewswireAlvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt

22.08.23GlobeNewswireAlvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET

31.07.23GlobeNewswireAlvotech Completes $100 Million Convertible Bond Private Placement

24.07.23GlobeNewswireTeva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership

17.07.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech SA - ALVO

29.06.23GlobeNewswireAlvotech Provides Regulatory Update on Second Biologics License Application for AVT02

12.06.23GlobeNewswireAlvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

31.05.23GlobeNewswireAlvotech to Participate in Jefferies Healthcare Conference

24.05.23GlobeNewswireAlvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe

19.05.23GlobeNewswireAlvotech Reports Financial Results for First three Months of 2023 and Provides Business Update

17.05.23GlobeNewswireAlvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit

15.05.23GlobeNewswireAlvotech Issues Annual Equality Report Covering 2022

10.05.23GlobeNewswireAlvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)

05.05.23GlobeNewswireAlvotech S.A. Annual General Meeting to be held June 6, 2023

Alvotech Registered News

Alvotech Registered News: auf dieser Seite finden Sie alle Alvotech Registered News und Nachrichten zur Alvotech Registered Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Alvotech Registered News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Alvotech Registered News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.